Beaker
Beaker.com
Spark Therapeutics: Where once I was blind, now I can see
Jeffrey Clark - Posted: 5/28/2015
Spark Therapeutics CEO Jeffrey Marrazzo discuss how advances in gene therapy are changing the way rare diseases are treated. Spark is a leader in the field of gene therapy, seeking to transform the lives of patients by developing one-time, life-alter[...]
In oncology? Better be at ASCO on Friday
Jeffrey Clark - Posted: 5/26/2015
ASCO starts later this week in Chicago, as one of the most critical and influential conferences for the life sciences meeting. ASCO 2015 is sponsored by every leading oncology drug company and brings together 30,000 oncology professionals from around[...]
Johnson and Johnson CEO on his strategy for acquisitions
Jeffrey Clark - Posted: 5/25/2015
Johnson & Johnson Chairman & CEO Alex Gorsky discusses the companys search for new scientific platforms and potential M&A prospects.
Johnson and Johnson CEO talks diversification and taxes
Jeffrey Clark - Posted: 5/21/2015
Johnson and Johnson CEO Alex Gorsky shares his point of view on the diversified strategy for the company, touching on the value of crossing over between medical devices, pharmaceuticals and consumer products. He also touches on the global economic im[...]
Johnson and Johnson CEO Alex Gorsky highlights innovation
Jeffrey Clark - Posted: 5/21/2015
In a series of interview clips on CNBC, Johnson & Johnson Chairman & CEO Alex Gorsky discusses new drugs in the companys development pipeline, with the biggest potential in oncology.
Vertex takes big step toward fulfilling lofty expectations
Jeffrey Clark - Posted: 5/19/2015
Vertex Pharmaceuticals experimental cystic fibrosis treatment Orkambi won the backing of a Food and Drug Administration advisory committee on Tuesday, which voted 12 to 1 to recommend approval of the drug.  The vote was important for Vertex, a compan[...]
Halozyme CEO talks products, drug delivers on CNBC
Jeffrey Clark - Posted: 5/18/2015
Halozyme CEO Helen Torley was in studio with CNBC this morning discussing a new drug that is disrupting the way cancer patients are treated.  Most relevant to Halozyme is the news about new drug delivery solutions for popular cancer treatments beyond[...]
Cool Technology: ConforMIS custom orthopedic implants
Jeffrey Clark - Posted: 5/14/2015
ConforMIS does something that no other knee replacement company does – design and manufacture customized knee implants for each patient. According to their product profile, no two are alike.   The company uses MRI imaging and 3D print[...]
The hottest new company in life sciences? Moderna Therapeutics.
Jeffrey Clark - Posted: 5/12/2015
This biggest secret in the life sciences is quickly becoming well known.  Just months ago, a Boston biotechnology company with fewer than 200 employees closed the he largest private round of fundraising in the history of the life sciences industry. T[...]
Stryker CEO: Growing, expanding into robotic surgery
Jeffrey Clark - Posted: 5/11/2015
Stryker CEO Kevin Lobo joins CNBC in studio to discuss the companys direction and specifically shares details on Strykers push into robotics. Remember that although Intuitive Surgical defined the category through the daVinci system, Stryker acquired [...]
Valeant CEO Pearson is the next Warren Buffett?
Jeffrey Clark - Posted: 5/8/2015
Pershing Square founder Bill Ackman, who spent most of 2014 linked with Valeants failed attempt to acquire Allergan, has touted Valeant as an up and coming Berkshire Hathaway and its CEO Mike Pearson as the second coming of Warren Buffett. Ackman mad[...]
GSK CEO Witty puts a bow on Novartis deal, business realignment
Jeffrey Clark - Posted: 5/7/2015
Today on CNBC, GlaxoSmithKline CEO Andrew Witty summed up the recent Novartis/GSK shuffle and business realignment as follows: Today, we are the worlds largest vaccine company, the largest OTC consumer healthcare business and a very strong pharmaceut[...]
Biogen CEO chases the holy grail of Alzheimers
Jeffrey Clark - Posted: 4/29/2015
At the World Medical Innovation Forum in Boston, Biogen CEO George Scangos discusses significant, yet early stage progress in a clinical trial for Alzheimers treatments. Scangos shared that his company would likely need to invest around $2.5 billion [...]
End of a run? Biotechnology stock, index drag down markets
Jeffrey Clark - Posted: 4/27/2015
CNBC pundits explore the recent pullback in biotechnology stocks, similar to a similar retrenchment in the spring of 2014. Those stocks down more than 10% today: Insys, Regulus, ImmunoGen, Akorn, and Aerie Pharmaceuticals. Celladon crashed by more th[...]
WSJ: Drug companies jacking prices to pay for deals
Jeffrey Clark - Posted: 4/27/2015
The Wall Street Journal has a strong article outlining one strategy pharmaceutical companies are using to fund this ongoing wave of mergers and acquisitions.  It seems that cost-savings and efficiency are the not the only financial factors when justi[...]
Mylan and Teva: Is bigger really better?
Jeffrey Clark - Posted: 4/22/2015
Mylan Labs was not overwhelmed thrilled by the unsolicited $40B bid from Teva Pharmaceuticals. And, in this instance (like many recent others), investors see a fit where the actual participating companies do not. With respect to Teva and Mylan, there[...]
NASDAQ CEO: The Golden Age of Biotech
Jeffrey Clark - Posted: 4/20/2015
Nasdaq CEO Robert Greifeld shares his views on recent trading activity in what he calls the golden age of biotechnology.
Aduro IPO skyrockets on high valuations
Jeffrey Clark - Posted: 4/16/2015
Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. This week on CNBC, CEO Stephen Isaacs shares his opinion on cancer research, recent company valuations, selling Aduros pipeline to Novartis and J&J,[...]
Robots, robots everywhere across the life sciences
Jeffrey Clark - Posted: 4/15/2015
Robots arent new to the life sciences industry. Intuitive Surgical launched the trend 15 years ago with its da Vinci Surgical System. Since then, the system has conducted more than 20,000 surgeries and has paved the way for robotic advancements in he[...]
Inovia CEO talks large grant, potential for Ebola vaccine
Jeffrey Clark - Posted: 4/14/2015
Inovio Pharmaceuticals CEO Dr. Joseph Kim discusses how the companys $45 million Ebola grant will impact the development of drugs for both the prevention and treatment of the disease.
Biotechnology companies mature, start paying dividends
Jeffrey Clark - Posted: 4/6/2015
It seems like just yesterday, when the biotechnology industry was in its infancy, led by names like Amgen, Chiron and Immunex. Fast forward what seems like an instant, and the industry is all grown up. New names have emerged with Biogen, Celgene, Gil[...]
Investing in life sciences?
Jeffrey Clark - Posted: 3/31/2015
CNBC contributor Barbara Ryan of Clermont Partners discusses investing in life sciences.
Sanofi chairman talks deals, but not new CEO
Jeffrey Clark - Posted: 3/30/2015
According to its Chairman Serge Weinger in an interview with French newspaper Los Echos, Sanofi  has examined acquisitions opportunities but does not view deal-making as indispensable to its future. We looked at potential deals but found the asking p[...]
WSJ offers backroom perspective of Allergan vs. Valeant saga
Jeffrey Clark - Posted: 3/26/2015
The Wall Street Journal has published an article entitled Inside the Allergan Battle, a detailed insiders synopsis of the chess game between Allergan, Valeant, Pershing Square and ultimately Actavis, that led to last years biggest corporate acquisiti[...]
Edwards CEO Mussallem addresses Senate
Jeffrey Clark - Posted: 3/25/2015
Advamed went to the Senate yesterday to represent the life sciences industry during a hearing to the Mike Mussallem, Chairman and CEO of Edwards Lifesciences, represented AdvaMed and the interests of the industry itself. Mussallems comments can be fo[...]
 
 Beaker.com
In oncology? Better be at[...]
ASCO starts later this week in Chicago, as one of the most critical and influential conferences for [...]
Johnson and Johnson CEO o[...]
Johnson & Johnson Chairman & CEO Alex Gorsky discusses the company’s search for new scientific platf[...]
Johnson and Johnson CEO t[...]
Johnson and Johnson CEO Alex Gorsky shares his point of view on the diversified strategy for the com[...]
Johnson and Johnson CEO A[...]
In a series of interview clips on CNBC, Johnson & Johnson Chairman & CEO Alex Gorsky discusses new d[...]
Halozyme CEO talks produc[...]
Halozyme CEO Helen Torley was in studio with CNBC this morning discussing a new drug that is disrupt[...]